Lubiprostone

Lubiprostone

drugbox
IUPAC_name = 7- [(1"R",3"R",6"R",7"R")-3-(1,1-difluoropentyl)-3-hydroxy-
8-oxo-2-oxabicyclo [4.3.0] non-7-yl] heptanoic acid



width = 280
CAS_number = 136790-76-6
ATC_prefix = A06
ATC_suffix = AX03
PubChem = 157920
DrugBank = APRD01298
C = 20 | H = 32 | F = 2 | O = 5
molecular_weight = 390.462 g/mol
bioavailability = Negligible
protein_bound = 94%
smiles = CCCCC(C1(CCC2C(O1)CC(=O)C2CCCCCCC(=O)O)O)(F)F
synonyms = Amitiza
RU-0211
SPI-0211
metabolism = Extensive, CYP not involved
elimination_half-life = Unknown (lubiprostone)
0.9–1.4 hours (main metabolite)
excretion = Renal (60%) and fecal (30%)
licence_US = Lubiprostone
pregnancy_US = C
legal_US = Rx-only
routes_of_administration = Oral

Lubiprostone (rINN, marketed under the trade name Amitiza) is a medication used in the management of idiopathic chronic constipation. It was approved by the U.S. Food and Drug Administration for this purpose on January 31, 2006.

Indications

Lubiprostone is a gastrointestinal agent used for the treatment of idiopathic chronic constipation. It is well-tolerated in adults, including elderly patients. As of July 20, 2006, Lubiprostone had not been studied in pediatric patients.

There is current research underway to determine the efficacy of Lubiprostone in patients with constipation-predominant IBS, postoperative bowel dysfunction, and opioid-induced bowel dysfunction.

Lubiprostone received approval from the United States Food and Drug Administration (FDA) on 04/29/2008 to treat Irritable Bowel Syndrome with constipation (IBS-C).

Mode of action

Lubiprostone is a bicyclic fatty acid (prostaglandin E1 derivative) which acts by specifically activating ClC-2 chloride channels on the apical aspect of gastrointestinal epithelial cells, producing a chloride-rich fluid secretion. These secretions soften the stool, increase motility, and promote spontaneous bowel movements (SBM).

Symptoms of constipation (pain, bloating) are usually improved within one week, and SBM may occur within one day.

Pharmacokinetics

Unlike many laxative products, Lubiprostone does not show signs of tolerance, dependency, or altered serum electrolyte concentration. There was no rebound effect following withdrawal of treatment, but a gradual return to pre-treatment bowel movement frequency should be expected.

Minimal distribution of the drug occurs beyond the immediate GI tissues. Lubiprostone is rapidly metabolized by reduction/oxidation, mediated by carbonyl reductase. There is no metabolic involvement of the hepatic cytochrome P450 system. The measurable metabolite, M3, exists in very low levels in plasma and makes up less than 10% of the total administered dose.

Data indicate that metabolism occurs locally in the stomach and jejunum.

ide effects

In clinical trials, the most common adverse event was nausea (31%). Other adverse events (≥5% of patients) included diarrhea (13%), headache (13%), abdominal distention (7%), abdominal pain (7%), flatulence (6%), sinusitis (5%) and vomiting (5%).

Contraindications

There are no current data on use in patients with hepatic and/or renal complications. The effects on pregnancy have not been studied in humans but testing in Guinea pigs resulted in fetal loss.

Lubiprostone is contraindicated in patients exhibiting chronic diarrhea or GI obstruction.

References

#cite book | last = Katzung | first = B.G. | title = Basic and Clinical Pharmacology, 10th edition | publisher = McGraw-Hill | date = 2007
#cite web | title = Clinical Pharmacology Online Database | url = http://www.clinicalpharmacology.com/default.asp | accessdate = 2007-02-28


Wikimedia Foundation. 2010.

Игры ⚽ Поможем написать курсовую

Look at other dictionaries:

  • lubiprostone — noun A medication used to treat idiopathic chronic constipation …   Wiktionary

  • lubiprostone — lu·bi·pros·tone (loo″bĭ prosґtōn) an activator of chloride channels of the apical membrane of the intestine that increases intestinal motility by stimulating the secretion of fluid into the lumen, used in the treatment of chronic… …   Medical dictionary

  • Irritable bowel syndrome — This article is about a functional disorder. For bowel inflammation, see Inflammatory bowel disease. Irritable bowel syndrome Classification and external resources ICD 10 K58 ICD 9 …   Wikipedia

  • Constipation — in a young child as seen by X ray. Circles represent areas of fecal matter (stool is opaque white surrounded by black bowel gas) …   Wikipedia

  • Laxative — Laxatives (purgatives, aperients) are foods, compounds, or drugs taken to induce bowel movements or to loosen the stool, most often taken to treat constipation. Certain stimulant, lubricant, and saline laxatives are used to evacuate the colon for …   Wikipedia

  • Phenolphthalein — IUPAC name 3,3 bis(4 hydroxyphenyl)isobenzofuran 1(3H) one …   Wikipedia

  • Magnesium sulfate — Anhydrous magnesium sulfate Epsomite (heptahydrate) …   Wikipedia

  • Lactulose — Systematic (IUPAC) name 4 O β D Galactopyranosyl β D fructofuranose OR (2S,3R,4S,5R,6R) 2 ((2R,3S,4S,5R) 4,5 dihydroxy 2,5 bis(hydroxymethyl) tetrahydrofuran 3 yloxy) 6 (hydroxymethyl)te …   Wikipedia

  • Bisacodyl — Systematic (IUPAC) name (pyridin 2 ylmethanediyl)dibenzene 4,1 diyl diacetate OR 4,4 (pyridin 2 ylmethylene)bis(4,1 phenylene) diacetate Clinical data …   Wikipedia

  • Methylnaltrexone — Systematic (IUPAC) name (5α) 17 (cyclopropylmethyl) 3,14 dihydroxy 17 methyl 4,5 epoxymorphinanium 17 ium 6 one Clinical data AHFS/ …   Wikipedia

Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”